A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

Basic Science Clinical Trial

Official title:
A Randomized, Placebo- and Positive-controlled, Crossover Study to Assess the Effect of Olpasiran (AMG 890) on QT/QTc Intervals in Healthy Subjects

Status Not yet recruiting

Clinical Trial Summary

The primary objective of the study is: • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Basic Science

Clinical Trial Details

NCT number	NCT06411860
Study type	Interventional
Source	Amgen
Contact	Amgen Call Center
Phone	866-572-6436
Email	medinfo@amgen.com
Status	Not yet recruiting
Phase	Phase 1
Start date	August 8, 2024
Completion date	October 28, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01860287` - The Effects of Buprenorphine on Responses to Verbal Tasks	Early Phase 1
Recruiting	`NCT05079516` - Neural Basis of Sensory Learning: Brain Regions	N/A
Recruiting	`NCT05953038` - LSD Occupancy of the Serotonin 2A Receptor in the Human Brain	Early Phase 1
Completed	`NCT03541473` - Phosphate Metabolites in Brain of Humans Aged 50+	N/A
Recruiting	`NCT03289949` - The Neurobiological Effect of 5-HT2AR Modulation	Phase 1
Recruiting	`NCT05739994` - Frontal and Parietal Contributions to Proprioception and Motor Skill Learning	N/A
Completed	`NCT04443647` - Influence of Oxytocin on Approach-avoidance Tendencies to Social and Non-social Stimuli	N/A
Recruiting	`NCT05374460` - Factors Affecting Sensory and Motor Learning	N/A
Recruiting	`NCT05124301` - Neural Basis of Sensory and Motor Learning: Functional Connections	N/A